Ziopharm Oncology (ZIOP) Reports First Patient Enrollment in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO
Tweet Send to a Friend
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) today announced that it has enrolled the first patient in its Phase 1 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
